ino-4201
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2015 (NCT02464670)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- EbolavirusImmunity, active
Ebolavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ino-4201
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04906629 | Phase 1 | Sep 1, 2021 | Defense Advanced Research Projects Agency, Global Urgent and Advanced Research and Development (GuardRX), Inovio Pharmaceuticals, University of Geneva, University of Genoa |
| NCT02464670 | Phase 1 | May 1, 2015 | Defense Advanced Research Projects Agency, GeneOne Life Science, Inovio Pharmaceuticals |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Defense Advanced Research Projects Agency | Government | 2 | 0 | 1 | 2015 |
| Inovio Pharmaceuticals | For profit | 2 | 1 | 1 | 2015 |
| GeneOne Life Science | For profit | 1 | 0 | 1 | 2015 |
| Global Urgent and Advanced Research and Development (GuardRX) | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Geneva | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Genoa | Academic/Hospital | 1 | 0 | 1 | 2021 |
6 organizations
Page 1 / 1